Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please show proof if you believe there is dilution. Here is an email response from Gerald the CEO of the Company on 1/10/2013 (after Biotech showcase presentation) that contradicts your assessment.
1 MONTH (12/26-1/26) AVG PPS = .109 (AVG VOLUME 22.9 mill; Total volume 481.5 mill)
IMO...strong base formed in the past month.
Just checked out their Twitter page...10,491 followers! That's very impressive, I wonder how many of those are shareholders.
:^)
Great post AE and with facts to back it up. Stickied!
I would be concerned with the OS increase if the company had no real products and/or no revenues. That is not the case here. From the recent PR ($500k in 6 weeks)...company is moving in the right direction.
Those that believe will buy, those that don't will not. Of course, you have those that want in at the lowest price possible by any means necessary.
Lots of experienced talent at $CERP! No doubt they don't want to lose NASDAQ status. With the bio-degradable direction of the World, CERP is setup perfectly to benefit.
That's weird, when I checked on my phone, it was showing all N/As, now on my computer it's showing trade info for 1/25. Guess it's still trading. :(
I guess one positive is the total volume traded was only 42K.
Let's get this party started!
I boughts in befour the hi yesturdai ands I berry happies! I tinks tis cumpanie is berry berri good.
"Do Not Buy or Sell on my Advice."
Will do.
.04's comin tomorrow
Listen to this man...he speaks the truth!!
"Anyone selling for a penny or two profit now will regret it very soon."
I agree with you!!
2013 STOCK OF THE YEAR and 2013 BIO-TECH CEO OF THE YEAR!!
Good thing you sold at .10. Good job.
Paul Pelosi, Jr.
Cereplast website:
http://www.cereplast.com/company/board-of-directors/#paul
"Paul Pelosi Jr. has 16 years experience in advising emerging and Fortune 500 companies in the areas of finance, infrastructure, sustainability and public policy...."
Wikipedia:
http://en.wikipedia.org/wiki/Paul_Pelosi,_Jr.
"Paul Francis Pelosi, Jr. (b. 23 January 1969) is the son of Nancy Pelosi (former Speaker of the United States House of Representatives) and a speaker on environmental policies[1] that encourage individuals and local governments to take a more active role in conserving natural resources and reducing carbon footprints...."
Don't follow blindly and be careful. MR pads their "core" group before the masses.
I would simply ignore this person like I did a long long time ago. If you look at his/her history, nothing but negative posts. I guess he/she is a glass empty type! LOL
Appears to be. Traded on 1/24/2013
http://www.boerse-berlin.com/index.php/Shares?isin=US02300T1097
(8 trades, ~123K shares)
Fair enough, IF it goes there, more buying opportunity.
FYI
1ST support level is .088
2ND support level is .076
AMBS hits 15s by tomorrow with news.
See I have a crystal ball too!
Thanks for the article. $AMBS snippet:
Amarantus BioScience (AMBS.OB) has recently announced new developments for its product candidate for Parkinson's recently. Two weeks ago, the company presented positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data demonstrate that unlike Glial cell-Derived Neurotrophic Factor (GDNF), MANF significantly reduces behavioral deficits, increases dopaminergic (DA) nerve terminal reinnervation of the striatum, and increases dopamine concentrations in the striatum when MANF is administered directly to the substantia nigra. Notably, at one point in time, GDNF was a very promising Parkinson's treatment being developed by Amgen (AMGN) before Amgen halted the GDNF trials.
"We are excited about our results with MANF as we have demonstrated superiority to GDNF in a number of key areas related to recovery of function in Parkinson's disease," added Dr. Joseph Rubinfeld, Amarantus advisor and Amgen Co-Founder. "We intend to continue to move our Parkinson's program forward, while also evaluating other disease indications for MANF with potentially accelerated regulatory pathways, including certain orphan diseases. This strategy may significantly reduce MANF's overall time to market versus a Parkinson's-only strategy."
RSI rising to power zone!
Would be nice...but doesn't have to be for longs to make good money.
That's the best time to get in. Before big $$$ comes!
Dr. Jerry's post, worth another bump.
Our managemnt is top notch, what a FIND !
You hit the nail on the head there. I don't know of any other BIO stocks trading down here with the advisory board that AMBS has. I wouldn't have believed it either until I saw Dr. Rubinfeld (AMGEN co-founder) co-present at the OneMedForum with the company's CSO Dr. Commissiong.
Deleting both of your posts. Please keep topic on AMBS. Thanks.
$AMBS starting to trade like a big boy now.
PR'ed $500K revenues in 6 weeks and market cap is < $1 million. Is that right?!!
MMs are experts at messing with ppl's fears. Probably took out a lot of stops on the walk down.
IMO, little (depending on who, minimal up or down) to no impact on PPS if JV with another small bio.
Found it. ADVAXIS presentation Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22, 2013
http://noble.mediasite.com/mediasite/Play/f83299afcf7b4bacae0c29236c8af0371d?catalog=7196f4ed-1981-4e62-afb2-e3a1f13bc7fb
Is there a webcast available to view?
This must be one hell of a JV!
The SoftBank/Sprint $20 billion merger is going to take less time to complete! LOL
Thanks for the 3s!
I agree with you Diesel, everytime I see a subpenny stock being touted with $1+ valuations...makes me think of that Sierra chix website.
Having a buyer like SOLO is HUGE HUGE HUGE!
If not AMGEN, many other potential sugar daddy
Abbott
Pfizer
Roche
Novartis
AstraZeneca
Sanofi
Johnson & Johnson
Merck
GlaxoSmithKline
Lilly
.
.
.
Just a matter of time. Hold for the gold.
Dr. Rubinfeld-founder of AMGEN- said, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen… MANF has the commercial potential to become a blockbuster drug."
$AMBS
I doubt Pfizer wants/needs RBCC. Realistically, RBCC doesn't have much to offer.